E - Glenmark

More documents

Recommendations

Info

Latin America Status in FY 2006 Acquired a company (Servycal) in Argentina: Provides opportunity to build an Oncology franchise across Latin America, going forward Expanded field force and also commenced commercial operations in several additional countries : Presence in 10 countries (including Brazil and Argentina) in Latin America Focused on specific therapeutic segments: Respiratory, Dermatology, Gynaecology. Grew by 197% over FY 2005 in Brazil Filed 19 dossiers in the key market of Brazil; obtained 11 product approvals and launched the products towards latter half of the year Completed the integration with India: ANVISA approval for Goa and Nasik plants, and 72-bed clinical trial unit for bio-equivalences
Latin America Going forward Expand presence in Oncology to other Latin American markets: use Argentina as the hub File over 50 dossiers in markets across Latin America with about 33 in Brazil. Launch 27 new products in Brazil. Margin expansion through increasing revenue for products filed from Indian parent Divisionalisation for greater focus – focus on high margin segments Achieve 100% growth in revenues over FY 2006
Page 2 and 3: Disclaimer This presentation has be
Page 4 and 5: Background History Identity / Scope
Page 6 and 7: Strategic roadmap: Transform into a
Page 8 and 9: Build proprietary pipeline of NCEs/
Page 10 and 11: NCE Research & Development Plan to
Page 12 and 13: NCE Pipeline Lead Target Indication
Page 14 and 15: Biologics research in Switzerland i
Page 16 and 17: Overview: Build/consolidate “bran
Page 18 and 19: India Formulations Current Status:
Page 20 and 21: India Formulations Moving forward,
Page 24 and 25: USA - Generic Formulations Progress
Page 26 and 27: Europe / UK - Start-up phase Strate
Page 28 and 29: Active Pharmaceutical Ingredients S
Page 30 and 31: Financials and Projections Performa
Page 32 and 33: Summary
Page 34: Thank you

E - Glenmark

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?